Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
Key facts
- Who runs it
- Unity Health Toronto
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 264 people, planned
- Started
- 29 Apr 2026
- Expected to end
- 24 Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Baloxavir
- Placebo Control
- Record updated
- 18 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- 18 years or older
- A positive test (PCR or RAT) for one of the pathogens included in the trial's domains (influenza A/B, or other future specified respiratory pathogens),
- Enrolled within 5 days of symptoms onset. However, this window may vary depending on the domain or specific interventions within each domain (for example 72 hours for Baloxavir)
- At least two symptoms commonly associated with respiratory infections, including:; rhinitis; cough; wheezing; sore throat; nasal congestion; shortness of breath; fatigue; rapid breathing; excessive mucus production; loss of smell or taste; hemoptysis; trouble sleeping or insomnia due to breathing difficulties; fever (defined for purposes of this study as >37.5°C/ 41)
Who cannot take part
- Previously randomized to TreatResp within the past 12 months
- Is scheduled for elective surgery or procedures requiring general anesthesia within the next two weeks
- Received a live viral vaccine within the last 14 days
- Currently participating in a clinical trial of a therapeutic agent for acute respiratory pathogen infection that is not/suspected not compatible with the study therapeutics
- Has severe hepatic impairment, or requires a live viral vaccine within the next seven days
- Has a significant impaired immunity (e.g., due to long-term oral steroids, chemotherapy, or an immune disorder)
- Is allergic to trial medications
- Is co-infected with viruses of interest
- Has advanced chronic kidney disease (CKD stage 3: eGFR ≥30 to <60 mL/min, and severe renal impairment (eGFR <30 ml/min, CKD stage 4-5)
- Admitted to hospital or in an ED for more than 24 hours
- Already taking a study therapeutic or contraindication to a study therapeutic
- Inability for participant or caregiver to provide informed consent; Additional eligibility criteria will be applied based on the intervention assigned. For instance, if a participant is randomized to an antiviral treatment, they must not have contraindications specific to that antiviral. This ensures that each treatment is evaluated in a population for whom it is most appropriate and safe; Baloxavir exclusion:
- Has a known or suspected pregnancy
- Is breastfeeding
- Is of childbearing potential and is not willing to use a highly effective contraceptive
- Requires immediate antiviral treatment or hospitalization as per the clinician's judgment
This trial is currently available in Canada.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.
The 2 groups in the trial
- Acute Influenza A/B - Matched placebo for BaloxavirPlacebo, for comparison
Usual Care (i.e., supportive care and symptom relief). Matching control placebo for Baloxavir - a single matching dose.
Treatment: Placebo Control
- Acute Influenza A/B - BaloxavirTreatment being tested
The adaptative platform trial will assess therapeutics for influenza A/B in out-patient setting. Interventions include: Baloxavir. Baloxavir dose: if weight \<80 kg: one 40 mg dose for 1 day; if weight ≥80kg, one 80 mg dose for one day.
Treatment: Baloxavir
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings
- Record updated
- 18 August 2026